Malaria Presenation


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Malaria Presenation

  1. 1. New Malaria Vaccine<br />Cassie Goodman and Dylan Karle<br />
  2. 2. Malaria<br />Mosquito-borne infectious disease caused by a parasite: Plasmodium<br />Parasite Plasmodium multiply in the liver and infect red blood cells<br />Transmitted through mosquitoes<br />Common symptoms: fever, <br /> headache, vomiting, muscle <br /> pains, chills<br />10-15 days after bite<br /><br />
  3. 3. Spread of Malaria<br />Widespread in tropical and sub-tropical areas<br />Parts of the Americas, Asia and Africa<br />Around 350-500 million cases a year that kill 1-3 million people<br />90% of Malaria-caused <br />deaths occur in Sub-Saharan <br />Africa<br />Majority are young children<br /> in Sub-Saharan Africa<br />Immunity can develop <br />naturally, but only after repeated <br />infections of different strains of <br />malaria<br />
  4. 4. Vaccine Need<br />Children are usually most vulnerable to malaria, because they have not built up a natural immunity like some adults<br />In Africa, 1 child dies of malaria every 30 seconds<br />There are some ways to prevent <br />malaria (killing infected <br />mosquitoes, bed nets) and some <br />medications to treat the parasite<br />An effective vaccine is the key step<br /> toward eradicating the disease <br />
  5. 5. FMP2.1/AS02A<br />Researchers are finding strong and long-lasting responses to a new vaccine for children<br />Being studied on children in Mali<br />The vaccine produces antibody levels that are as high or higher then those of people who have become naturally immune<br />The vaccine can reproduce the natural protective immunity that usually takes years of intense exposure to malaria to develop<br />
  6. 6. FMP2.1/AS02A<br />Consists of a form of the AMA-1 protein and the AS02 Adjuvant System<br />Adjuvant System is a compound that boosts the immune response to the vaccine<br />Based on a single strain of the falciparum malaria parasite – the most common and deadliest form of the parasite found in Africa<br />Targets the blood stage<br />The period after the mosquito bite – when the parasite multiplies in the blood<br />Causes the disease and death<br />
  7. 7. Studies<br />Other blood stage vaccines have been tested but none have shown the ability to prevent malaria<br />Previous studies with the new vaccine in the US and Mali have found the vaccine to be safe and produce strong immune responses in adults<br />Tested in 100 Malian children ages 1-6<br />Children were randomly assigned either one of three escalating doses of the new vaccine or a control rabies vaccine<br />All three doses of the vaccine proved to be safe, well tolerated, and had strong antibody responses that were sustained for at least 1 year<br />
  8. 8. More Studies<br />Since the earlier trial, researchers are now conducting a larger trial of 400 Malian children <br />This trial will also examine if the vaccine can protect against multiple malaria parasites – even though it is only based on a single strain<br />Scientists hope that the vaccine could be combined with other vaccines and create a highly protective multi-component immunization <br />
  9. 9. Sources<br /><br /><br />